Cargando…

Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab

Cetuximab-based chemoimmunotherapy has been the standard of care for recurrent or metastatic squamous cell carcinoma of the head and neck (r/m SCCHN) for more than a decade. To date, no predictive or prognostic biomarkers have been established to further guide the systemic treatment with cetuximab-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Pogorzelski, Michael, Hilser, Thomas, Ting, Saskia C., Kansy, Benjamin, Gauler, Thomas C., Stuschke, Martin, Schmid, Kurt W., Lang, Stephan, Grünwald, Viktor, Schuler, Martin, Kasper, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155676/
https://www.ncbi.nlm.nih.gov/pubmed/34055606
http://dx.doi.org/10.3389/fonc.2021.635096
_version_ 1783699260785557504
author Pogorzelski, Michael
Hilser, Thomas
Ting, Saskia C.
Kansy, Benjamin
Gauler, Thomas C.
Stuschke, Martin
Schmid, Kurt W.
Lang, Stephan
Grünwald, Viktor
Schuler, Martin
Kasper, Stefan
author_facet Pogorzelski, Michael
Hilser, Thomas
Ting, Saskia C.
Kansy, Benjamin
Gauler, Thomas C.
Stuschke, Martin
Schmid, Kurt W.
Lang, Stephan
Grünwald, Viktor
Schuler, Martin
Kasper, Stefan
author_sort Pogorzelski, Michael
collection PubMed
description Cetuximab-based chemoimmunotherapy has been the standard of care for recurrent or metastatic squamous cell carcinoma of the head and neck (r/m SCCHN) for more than a decade. To date, no predictive or prognostic biomarkers have been established to further guide the systemic treatment with cetuximab-based chemoimmunotherapy in r/m SCCHN. Against this background, we retrospectively analyzed clinical and blood-based parameters from 218 r/m SCCHN patients treated with chemoimmunotherapy including cetuximab. Multivariate Cox-regression models were used to assess their prognostic or predictive value. Eastern Co-operative Oncology Group (ECOG) performance status (≥2), older age (≥61.8 years), anemia (hemoglobin <11.80), and increased neutrophil-to-lymphocyte ratio (NLR ≥5.73) were independently and strongly associated with inferior overall survival (OS). To group patients according to risk profiles we established a prognostic clinical score (PCS) that can easily be used in clinical practice. The PCS stratified the cohort into low, intermediate, poor or very poor risk subgroups with median OS times of 23.4, 12.1, 7.5, and 4.0 months, respectively. Patients with low risk PCS had a prolonged progression-free survival (PFS) and increased overall response rate (ORR) under first-line cetuximab-based therapy. Interestingly, only patients with low and intermediate risk benefitted from the more intensive first-line cisplatin/cetuximab combination compared to carboplatin/cetuximab therapy, whereas the intensity of first-line treatment had no impact in the poor and very poor risk subgroups. Following external validation, particularly in the context of newly established first-line options, the PCS may guide clinical decision making and serve for stratification of patients with r/m SCCHN in future clinical trials.
format Online
Article
Text
id pubmed-8155676
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81556762021-05-28 Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab Pogorzelski, Michael Hilser, Thomas Ting, Saskia C. Kansy, Benjamin Gauler, Thomas C. Stuschke, Martin Schmid, Kurt W. Lang, Stephan Grünwald, Viktor Schuler, Martin Kasper, Stefan Front Oncol Oncology Cetuximab-based chemoimmunotherapy has been the standard of care for recurrent or metastatic squamous cell carcinoma of the head and neck (r/m SCCHN) for more than a decade. To date, no predictive or prognostic biomarkers have been established to further guide the systemic treatment with cetuximab-based chemoimmunotherapy in r/m SCCHN. Against this background, we retrospectively analyzed clinical and blood-based parameters from 218 r/m SCCHN patients treated with chemoimmunotherapy including cetuximab. Multivariate Cox-regression models were used to assess their prognostic or predictive value. Eastern Co-operative Oncology Group (ECOG) performance status (≥2), older age (≥61.8 years), anemia (hemoglobin <11.80), and increased neutrophil-to-lymphocyte ratio (NLR ≥5.73) were independently and strongly associated with inferior overall survival (OS). To group patients according to risk profiles we established a prognostic clinical score (PCS) that can easily be used in clinical practice. The PCS stratified the cohort into low, intermediate, poor or very poor risk subgroups with median OS times of 23.4, 12.1, 7.5, and 4.0 months, respectively. Patients with low risk PCS had a prolonged progression-free survival (PFS) and increased overall response rate (ORR) under first-line cetuximab-based therapy. Interestingly, only patients with low and intermediate risk benefitted from the more intensive first-line cisplatin/cetuximab combination compared to carboplatin/cetuximab therapy, whereas the intensity of first-line treatment had no impact in the poor and very poor risk subgroups. Following external validation, particularly in the context of newly established first-line options, the PCS may guide clinical decision making and serve for stratification of patients with r/m SCCHN in future clinical trials. Frontiers Media S.A. 2021-05-13 /pmc/articles/PMC8155676/ /pubmed/34055606 http://dx.doi.org/10.3389/fonc.2021.635096 Text en Copyright © 2021 Pogorzelski, Hilser, Ting, Kansy, Gauler, Stuschke, Schmid, Lang, Grünwald, Schuler and Kasper https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Pogorzelski, Michael
Hilser, Thomas
Ting, Saskia C.
Kansy, Benjamin
Gauler, Thomas C.
Stuschke, Martin
Schmid, Kurt W.
Lang, Stephan
Grünwald, Viktor
Schuler, Martin
Kasper, Stefan
Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
title Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
title_full Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
title_fullStr Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
title_full_unstemmed Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
title_short Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
title_sort identification of a prognostic clinical score for patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with systemic therapy including cetuximab
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155676/
https://www.ncbi.nlm.nih.gov/pubmed/34055606
http://dx.doi.org/10.3389/fonc.2021.635096
work_keys_str_mv AT pogorzelskimichael identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT hilserthomas identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT tingsaskiac identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT kansybenjamin identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT gaulerthomasc identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT stuschkemartin identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT schmidkurtw identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT langstephan identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT grunwaldviktor identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT schulermartin identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab
AT kasperstefan identificationofaprognosticclinicalscoreforpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandnecktreatedwithsystemictherapyincludingcetuximab